RU2017145628A - Композиции антагонистов нейрокинина-1 для внутривенного введения - Google Patents
Композиции антагонистов нейрокинина-1 для внутривенного введения Download PDFInfo
- Publication number
- RU2017145628A RU2017145628A RU2017145628A RU2017145628A RU2017145628A RU 2017145628 A RU2017145628 A RU 2017145628A RU 2017145628 A RU2017145628 A RU 2017145628A RU 2017145628 A RU2017145628 A RU 2017145628A RU 2017145628 A RU2017145628 A RU 2017145628A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- compound
- formula
- triglyceride
- pharmaceutical composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 53
- 238000001990 intravenous administration Methods 0.000 title claims 13
- 229940127387 Neurokinin 1 Antagonists Drugs 0.000 title 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 42
- 239000008194 pharmaceutical composition Substances 0.000 claims 37
- 150000001875 compounds Chemical class 0.000 claims 35
- 238000000034 method Methods 0.000 claims 28
- 150000003839 salts Chemical class 0.000 claims 23
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 14
- BKVAAWMQOQLENB-UHFFFAOYSA-N 15-hydroxy stearic acid Chemical compound CCCC(O)CCCCCCCCCCCCCC(O)=O BKVAAWMQOQLENB-UHFFFAOYSA-N 0.000 claims 11
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 11
- 229960003511 macrogol Drugs 0.000 claims 11
- 206010047700 Vomiting Diseases 0.000 claims 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 238000002512 chemotherapy Methods 0.000 claims 6
- 150000003904 phospholipids Chemical class 0.000 claims 6
- 239000003549 soybean oil Substances 0.000 claims 6
- 235000012424 soybean oil Nutrition 0.000 claims 6
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 5
- 150000004668 long chain fatty acids Chemical class 0.000 claims 5
- 239000000693 micelle Substances 0.000 claims 5
- 229960002446 octanoic acid Drugs 0.000 claims 5
- 230000008673 vomiting Effects 0.000 claims 5
- 241000288906 Primates Species 0.000 claims 4
- 230000001154 acute effect Effects 0.000 claims 4
- 239000002111 antiemetic agent Substances 0.000 claims 4
- 229940125683 antiemetic agent Drugs 0.000 claims 4
- 230000003111 delayed effect Effects 0.000 claims 4
- 239000000839 emulsion Substances 0.000 claims 4
- 239000004530 micro-emulsion Substances 0.000 claims 4
- 239000008363 phosphate buffer Substances 0.000 claims 4
- 206010028813 Nausea Diseases 0.000 claims 3
- -1 alkali metal salts Chemical class 0.000 claims 3
- 239000000872 buffer Substances 0.000 claims 3
- 235000011187 glycerol Nutrition 0.000 claims 3
- 238000001802 infusion Methods 0.000 claims 3
- 230000008693 nausea Effects 0.000 claims 3
- 239000003921 oil Substances 0.000 claims 3
- 235000019198 oils Nutrition 0.000 claims 3
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 206010018910 Haemolysis Diseases 0.000 claims 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims 2
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 claims 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 2
- 235000019483 Peanut oil Nutrition 0.000 claims 2
- 208000031649 Postoperative Nausea and Vomiting Diseases 0.000 claims 2
- 235000019486 Sunflower oil Nutrition 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000001430 anti-depressive effect Effects 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 229940005513 antidepressants Drugs 0.000 claims 2
- CJPQIRJHIZUAQP-MRXNPFEDSA-N benalaxyl-M Chemical compound CC=1C=CC=C(C)C=1N([C@H](C)C(=O)OC)C(=O)CC1=CC=CC=C1 CJPQIRJHIZUAQP-MRXNPFEDSA-N 0.000 claims 2
- 239000004359 castor oil Substances 0.000 claims 2
- 235000019438 castor oil Nutrition 0.000 claims 2
- 229960001777 castor oil Drugs 0.000 claims 2
- 150000001768 cations Chemical class 0.000 claims 2
- 239000003240 coconut oil Substances 0.000 claims 2
- 235000019864 coconut oil Nutrition 0.000 claims 2
- 235000005687 corn oil Nutrition 0.000 claims 2
- 239000002285 corn oil Substances 0.000 claims 2
- 235000012343 cottonseed oil Nutrition 0.000 claims 2
- 239000002385 cottonseed oil Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims 2
- 229940093471 ethyl oleate Drugs 0.000 claims 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 2
- 230000008588 hemolysis Effects 0.000 claims 2
- 229940072106 hydroxystearate Drugs 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 claims 2
- 239000004006 olive oil Substances 0.000 claims 2
- 235000008390 olive oil Nutrition 0.000 claims 2
- 235000021315 omega 9 monounsaturated fatty acids Nutrition 0.000 claims 2
- 239000000312 peanut oil Substances 0.000 claims 2
- 239000008159 sesame oil Substances 0.000 claims 2
- 235000011803 sesame oil Nutrition 0.000 claims 2
- 239000010686 shark liver oil Substances 0.000 claims 2
- 229940069764 shark liver oil Drugs 0.000 claims 2
- 239000002600 sunflower oil Substances 0.000 claims 2
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 claims 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 206010066962 Procedural nausea Diseases 0.000 claims 1
- 206010066963 Procedural vomiting Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims 1
- 150000003863 ammonium salts Chemical class 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000001062 anti-nausea Effects 0.000 claims 1
- 230000003457 anti-vomiting effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 239000002736 nonionic surfactant Substances 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 239000008389 polyethoxylated castor oil Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000012064 sodium phosphate buffer Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
- A01N43/42—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23412909P | 2009-08-14 | 2009-08-14 | |
| US61/234,129 | 2009-08-14 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012109405A Division RU2642234C2 (ru) | 2009-08-14 | 2010-08-12 | Композиции антагонистов нейрокинина-1 для внутривенного введения |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2017145628A true RU2017145628A (ru) | 2019-02-19 |
Family
ID=43586486
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017145628A RU2017145628A (ru) | 2009-08-14 | 2010-08-12 | Композиции антагонистов нейрокинина-1 для внутривенного введения |
| RU2012109405A RU2642234C2 (ru) | 2009-08-14 | 2010-08-12 | Композиции антагонистов нейрокинина-1 для внутривенного введения |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012109405A RU2642234C2 (ru) | 2009-08-14 | 2010-08-12 | Композиции антагонистов нейрокинина-1 для внутривенного введения |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9101615B2 (https=) |
| EP (2) | EP3143996A1 (https=) |
| JP (2) | JP5860399B2 (https=) |
| KR (1) | KR101834577B1 (https=) |
| CN (2) | CN102573475B (https=) |
| AU (1) | AU2010282483B2 (https=) |
| BR (1) | BR112012003263A2 (https=) |
| CA (1) | CA2770403C (https=) |
| ES (1) | ES2609640T3 (https=) |
| IL (1) | IL217942A0 (https=) |
| MX (1) | MX336071B (https=) |
| RU (2) | RU2017145628A (https=) |
| SG (2) | SG10201407538WA (https=) |
| TW (2) | TW201604195A (https=) |
| WO (1) | WO2011019911A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2662374A1 (en) * | 2006-04-05 | 2013-11-13 | OPKO Health, Inc. | Salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}-methyl]-8-phenyl-1,7 -diaza-spiro[4.5]decan-2-one and preparation process therefor |
| SG10201500028RA (en) | 2006-04-05 | 2015-02-27 | Opko Health Inc | Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same |
| AR066191A1 (es) | 2007-03-22 | 2009-08-05 | Schering Corp | Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona |
| KR101719004B1 (ko) | 2008-09-05 | 2017-03-22 | 옵코 헬스, 인크. | 8-［｛1-（3,5-비스-（트리플루오로메틸）페닐）-에톡시｝-메틸］-8-페닐-1,7-디아자-스피로［4.5］데칸-2-온 화합물의 합성 방법 및 중간체 |
| CN102573475B (zh) | 2009-08-14 | 2016-01-20 | 欧科生医股份有限公司 | 神经激肽-1拮抗剂的静脉内制剂 |
| AR097683A1 (es) * | 2013-09-26 | 2016-04-06 | Lilly Co Eli | Compuestos y uso para la preparación de agentes de formación de imagen tau y formulaciones para la formación de imagen tau |
| WO2016044784A1 (en) | 2014-09-19 | 2016-03-24 | Heron Therapeutics, Inc. | Emulson formulations of aprepitant |
| CA2978736C (en) | 2015-03-04 | 2023-11-07 | Vanda Pharmaceuticals Inc. | Dosing regimen of tradipitant |
| US20180250270A1 (en) | 2015-09-11 | 2018-09-06 | Chase Pharmaceuticals Corporation | Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system |
| US9974742B2 (en) * | 2016-02-01 | 2018-05-22 | Heron Therapeutics, Inc. | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
| KR20180118136A (ko) * | 2016-02-01 | 2018-10-30 | 헤론 테라퓨틱스 인코포레이티드 | Nk-1 수용체 길항제를 포함하는 에멀젼 |
| US20190175702A1 (en) * | 2016-08-03 | 2019-06-13 | Zhuhai Beihai Biotech Co., Ltd. | Formulations of fosaprepitant and aprepitant |
| US20190307734A1 (en) * | 2016-11-21 | 2019-10-10 | Zhuhai Beihai Biotech Co., Ltd. | Formulations of rolapitant |
| IL312486B2 (en) | 2017-04-10 | 2025-05-01 | Chase Therapeutics Corp | NK1 antagonist combination and method for treating synucleinopathies |
| WO2019005830A1 (en) * | 2017-06-26 | 2019-01-03 | Fordoz Pharma Corp. | NANOSOME FORMULATIONS OF APREPITANT AND METHODS AND APPLICATIONS THEREOF |
| CN121221782A (zh) | 2017-06-30 | 2025-12-30 | 傲拓神经科学公司 | 用于治疗抑郁的nk-1拮抗剂组合物和方法 |
| CN109200018A (zh) * | 2017-07-04 | 2019-01-15 | 南京诺瑞特医药科技有限公司 | 含有奈妥吡坦的微乳制剂 |
| CN108703950B (zh) * | 2018-08-27 | 2021-04-20 | 辅必成（上海）医药科技有限公司 | 一种罗拉吡坦的乳剂注射液 |
| CN109453115A (zh) * | 2018-12-25 | 2019-03-12 | 广州白云山汉方现代药业有限公司 | 一种罗拉匹坦静脉注射乳剂及其制备方法和应用 |
| CN109394693A (zh) * | 2018-12-25 | 2019-03-01 | 广州白云山汉方现代药业有限公司 | 一种罗拉匹坦乳剂及其制备方法和应用 |
| EP3991730A4 (en) | 2019-06-28 | 2023-08-09 | Shanghai Shengdi Pharmaceutical Co., Ltd | NEUROKININ-1 ANTAGONIST |
| AU2021246889A1 (en) | 2020-04-03 | 2022-10-13 | Nerre Therapeutics Limited | An NK-1 receptor antagonist for treating a disease selecting from sepsis, septic shock,, acute respiratory distress syndrome (ARDS) or multiple organ dysfunction syndrome (MODS) |
| CA3177477A1 (en) | 2020-06-02 | 2021-12-09 | Nerre Therapeutics Limited | Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs |
| AU2021407138A1 (en) * | 2020-12-25 | 2023-06-29 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Use of nk1 antagonist prodrug compound in combination with 5-ht3 receptor antagonist |
| EP4464712A4 (en) * | 2022-01-12 | 2025-07-23 | Jiangsu Hengrui Pharmaceuticals Co Ltd | CRYSTALLINE FORM OF A NEUROKININ-1 ANTAGONIST PRODRUG COMPOUND |
| CA3247908A1 (en) * | 2022-01-12 | 2025-07-10 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | PHARMACEUTICAL COMPOSITION COMPRISING A NEUROKIN-1 ANTAGONIST PROMEDICINE COMPOUND |
| CN119528985A (zh) | 2023-08-28 | 2025-02-28 | 科睿迪(南京)医药科技有限公司 | 神经激肽-1受体拮抗剂化合物 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0338372A3 (en) * | 1988-04-22 | 1991-10-09 | American Cyanamid Company | Solubilized pro-drugs |
| HUT60139A (en) * | 1989-07-07 | 1992-08-28 | Endorecherche Inc | Process for producing pharmaceutical composition suitable for treating prostate cancer connected with androgen |
| US5610140A (en) * | 1991-04-01 | 1997-03-11 | Cortech, Inc. | Bradykinin receptor antagonists with neurokinin receptor blocking activity |
| AU678409B2 (en) | 1992-10-28 | 1997-05-29 | Merck Sharp & Dohme Limited | 4-arylmethyloxymethyl piperidines as tachykinin antagonists |
| US5661162A (en) | 1992-12-14 | 1997-08-26 | Merck Sharp & Dohme Limited | 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperdines as tachykinin receptor antagonists |
| GB9305718D0 (en) * | 1993-03-19 | 1993-05-05 | Glaxo Group Ltd | Medicaments |
| ATE170174T1 (de) | 1994-01-13 | 1998-09-15 | Merck Sharp & Dohme | Gem-bissubstituierte azazyclische tachykinin- antagonisten |
| WO1996026726A1 (en) | 1995-02-28 | 1996-09-06 | Hoechst Marion Roussel, Inc. | Pharmaceutical composition for piperidinoalkanol compounds |
| SE9503143D0 (sv) * | 1995-09-12 | 1995-09-12 | Astra Ab | New preparation |
| GB9601680D0 (en) | 1996-01-27 | 1996-03-27 | Pfizer Ltd | Therapeutic agents |
| ATE265209T1 (de) | 1996-07-17 | 2004-05-15 | Merck & Co Inc | Änderung des zirkadischen rhythmus mit nicht- peptidischen neurokinin-1 rezeptor antagonisten |
| CA2287397A1 (en) | 1997-04-24 | 1998-10-29 | Merck Sharp & Dohme Limited | Use of an nk-1 receptor antagonist and an ssri for treating obesity |
| JP3571511B2 (ja) * | 1997-11-11 | 2004-09-29 | トーアエイヨー株式会社 | 経皮吸収製剤 |
| US6380242B1 (en) | 1998-12-23 | 2002-04-30 | Nps Allelix Corp. | N-alkylamino-indoles for the treatment of migraine |
| MXPA01011981A (es) | 1999-05-24 | 2003-09-04 | Sonus Pharma Inc | Vehiculo de emulsion para farmacos poco solubles. |
| US6436928B1 (en) | 1999-12-17 | 2002-08-20 | Schering Corporation | Selective neurokinin antagonists |
| ES2258485T3 (es) | 1999-12-17 | 2006-09-01 | Schering Corporation | Antagonistas selectivos de neuroquinina. |
| US6499984B1 (en) | 2000-05-22 | 2002-12-31 | Warner-Lambert Company | Continuous production of pharmaceutical granulation |
| MY128450A (en) * | 2000-05-24 | 2007-02-28 | Upjohn Co | 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| JP2004526706A (ja) | 2001-02-12 | 2004-09-02 | テバ ファーマシューティカル インダストリーズ リミティド | オクスカルバゼピンの新しい結晶形態及びそれらの調製方法 |
| ATE374183T1 (de) | 2001-11-13 | 2007-10-15 | Schering Corp | Nk1-antagonisten |
| PE20030762A1 (es) * | 2001-12-18 | 2003-09-05 | Schering Corp | Compuestos heterociclicos como antagonistas nk1 |
| AU2003277299B2 (en) * | 2002-04-10 | 2009-12-10 | Conforma Therapeutics Corporation | Drug formulations having long and medium chain triglycerides |
| ATE358482T1 (de) | 2002-07-03 | 2007-04-15 | Schering Corp | 1-amido-4-phenyl-4-benzyloxymethyl-piperidin derivative und verwandte verbindungen als neurokinin-1 (nk-1) antagonsisten zur behandlung von erbrechen, depressionen, angstzustände und husten |
| US7534913B2 (en) | 2002-07-18 | 2009-05-19 | Teva Pharmaceutica Industries Ltd. | Crystalline form of nateglinide |
| US7323459B2 (en) | 2002-12-24 | 2008-01-29 | Teva Pharmaceutical Industries Ltd. | Crystal forms, methods for their preparation and method for preparation of olanzapine |
| GB0321256D0 (en) | 2003-09-11 | 2003-10-08 | Generics Uk Ltd | Novel crystalline compounds |
| EP1682545B1 (en) | 2003-10-03 | 2007-12-12 | Pfizer Limited | Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation |
| AU2004308935A1 (en) * | 2003-12-22 | 2005-07-14 | Schering Corporation | Pharmaceutical compositions |
| JP2008505107A (ja) | 2004-07-01 | 2008-02-21 | シェーリング コーポレイション | Ｎｋ１アンタゴニストとしてのピペリジン誘導体 |
| US7871632B2 (en) * | 2004-07-12 | 2011-01-18 | Adventrx Pharmaceuticals, Inc. | Compositions for delivering highly water soluble drugs |
| WO2006060580A1 (en) * | 2004-11-30 | 2006-06-08 | Myriad Genetics, Inc. | Therapeutic formulations |
| CN100367951C (zh) | 2005-12-16 | 2008-02-13 | 石药集团恩必普药业有限公司 | 丁苯酞静脉乳剂及其应用 |
| PE20071019A1 (es) * | 2006-03-06 | 2007-10-29 | Wyeth Corp | Formulaciones farmaceuticas liquidas y semi-solidas que comprenden un modulador de receptores estrogenicos |
| EP2662374A1 (en) | 2006-04-05 | 2013-11-13 | OPKO Health, Inc. | Salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}-methyl]-8-phenyl-1,7 -diaza-spiro[4.5]decan-2-one and preparation process therefor |
| SG10201500028RA (en) | 2006-04-05 | 2015-02-27 | Opko Health Inc | Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same |
| CN101110758A (zh) | 2006-07-21 | 2008-01-23 | 华为技术有限公司 | 建立紧急会话的方法、系统及代理呼叫会话控制功能 |
| MX2009001208A (es) | 2006-08-07 | 2009-04-14 | Stiefel Laboratories | Compuestos cristalinos antifungicos. |
| WO2008098374A1 (en) * | 2007-02-16 | 2008-08-21 | Affinium Pharmaceuticals, Inc. | Salts, prodrugs and polymorphs of fab i inhibitors |
| AR065802A1 (es) | 2007-03-22 | 2009-07-01 | Schering Corp | Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas |
| AR066191A1 (es) | 2007-03-22 | 2009-08-05 | Schering Corp | Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona |
| KR101719004B1 (ko) | 2008-09-05 | 2017-03-22 | 옵코 헬스, 인크. | 8-［｛1-（3,5-비스-（트리플루오로메틸）페닐）-에톡시｝-메틸］-8-페닐-1,7-디아자-스피로［4.5］데칸-2-온 화합물의 합성 방법 및 중간체 |
| CN102573475B (zh) | 2009-08-14 | 2016-01-20 | 欧科生医股份有限公司 | 神经激肽-1拮抗剂的静脉内制剂 |
-
2010
- 2010-08-12 CN CN201080046905.2A patent/CN102573475B/zh not_active Expired - Fee Related
- 2010-08-12 CA CA2770403A patent/CA2770403C/en active Active
- 2010-08-12 RU RU2017145628A patent/RU2017145628A/ru not_active Application Discontinuation
- 2010-08-12 BR BR112012003263A patent/BR112012003263A2/pt not_active Application Discontinuation
- 2010-08-12 ES ES10808756.0T patent/ES2609640T3/es active Active
- 2010-08-12 WO PCT/US2010/045317 patent/WO2011019911A1/en not_active Ceased
- 2010-08-12 AU AU2010282483A patent/AU2010282483B2/en not_active Ceased
- 2010-08-12 JP JP2012524868A patent/JP5860399B2/ja not_active Expired - Fee Related
- 2010-08-12 RU RU2012109405A patent/RU2642234C2/ru not_active IP Right Cessation
- 2010-08-12 MX MX2012001872A patent/MX336071B/es unknown
- 2010-08-12 CN CN201510830177.9A patent/CN105503870A/zh active Pending
- 2010-08-12 SG SG10201407538WA patent/SG10201407538WA/en unknown
- 2010-08-12 EP EP16181864.6A patent/EP3143996A1/en not_active Withdrawn
- 2010-08-12 EP EP10808756.0A patent/EP2464230B1/en not_active Not-in-force
- 2010-08-12 KR KR1020127006576A patent/KR101834577B1/ko not_active Expired - Fee Related
- 2010-08-12 SG SG2012010146A patent/SG178403A1/en unknown
- 2010-08-13 TW TW104121014A patent/TW201604195A/zh unknown
- 2010-08-13 US US12/855,889 patent/US9101615B2/en active Active
- 2010-08-13 TW TW099127158A patent/TWI498329B/zh not_active IP Right Cessation
-
2012
- 2012-02-05 IL IL217942A patent/IL217942A0/en unknown
-
2015
- 2015-07-28 US US14/811,342 patent/US20160024092A1/en not_active Abandoned
- 2015-11-04 JP JP2015216374A patent/JP6308991B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2464230B1 (en) | 2016-10-05 |
| US20160024092A1 (en) | 2016-01-28 |
| MX2012001872A (es) | 2012-04-11 |
| US9101615B2 (en) | 2015-08-11 |
| RU2642234C2 (ru) | 2018-01-24 |
| JP2013501806A (ja) | 2013-01-17 |
| JP2016041734A (ja) | 2016-03-31 |
| EP3143996A1 (en) | 2017-03-22 |
| JP6308991B2 (ja) | 2018-04-11 |
| AU2010282483B2 (en) | 2014-09-04 |
| CN102573475B (zh) | 2016-01-20 |
| TWI498329B (zh) | 2015-09-01 |
| KR20120060215A (ko) | 2012-06-11 |
| EP2464230A1 (en) | 2012-06-20 |
| MX336071B (es) | 2016-01-06 |
| EP2464230A4 (en) | 2013-01-02 |
| TW201111382A (en) | 2011-04-01 |
| TW201604195A (zh) | 2016-02-01 |
| WO2011019911A1 (en) | 2011-02-17 |
| SG10201407538WA (en) | 2015-01-29 |
| US20110038925A1 (en) | 2011-02-17 |
| CN105503870A (zh) | 2016-04-20 |
| RU2012109405A (ru) | 2013-09-20 |
| ES2609640T3 (es) | 2017-04-21 |
| BR112012003263A2 (pt) | 2015-09-22 |
| JP5860399B2 (ja) | 2016-02-16 |
| AU2010282483A1 (en) | 2012-03-01 |
| CN102573475A (zh) | 2012-07-11 |
| IL217942A0 (en) | 2012-03-29 |
| CA2770403A1 (en) | 2011-02-17 |
| SG178403A1 (en) | 2012-03-29 |
| KR101834577B1 (ko) | 2018-03-05 |
| CA2770403C (en) | 2020-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017145628A (ru) | Композиции антагонистов нейрокинина-1 для внутривенного введения | |
| JP2013501806A5 (https=) | ||
| US10953018B2 (en) | Emulsion formulations of aprepitant | |
| US12115254B2 (en) | Methods of use of emulsion formulations of an NK-1 receptor antagonist | |
| CN1113650C (zh) | 自体乳化剂形式的亲脂性化合物的药物组合物 | |
| KR101267901B1 (ko) | 프로스타글란딘 ｅ₁을 포함하는 에멀션 조성물 | |
| CA2520886A1 (en) | Pharmaceutical compositions for hepatitis c viral protease inhibitors | |
| CN100367951C (zh) | 丁苯酞静脉乳剂及其应用 | |
| EP3411013A1 (en) | Emulsion comprising an nk-1 receptor antagonist | |
| US20030100511A1 (en) | Therapeutic compositions containing glutathione analogs | |
| KR20140016926A (ko) | 활성제로서 페닐아미노피리미딘 유도체를 포함하는 제제 | |
| RS52131B (sr) | Nove kompozicije na bazi taksoida | |
| EP1517682B1 (en) | Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant | |
| KR101353443B1 (ko) | 데옥시콜린산 나트륨이 없는 포스파티딜콜린 함유 주사제 조성물 및 이의 제조방법 | |
| US20190231688A1 (en) | Method of administering emulsion formulations of an nk-1 receptor antagonist | |
| WO2013008083A1 (en) | Pharmaceutical composition for enhancing anticancer efficacy of tamoxifen | |
| JP4638053B2 (ja) | レトロウイルスプロテアーゼインヒビター用医薬エマルジョン | |
| RU2839882C1 (ru) | Микроэмульсионная лекарственная форма для перорального введения | |
| KR101012903B1 (ko) | 나노입자 형성을 이용하는 리세드로네이트 경질캡슐 | |
| WO2021162106A1 (ja) | 溶解剤 | |
| KR20070096142A (ko) | 흡수율 증진을 위한 타크로리무스 나노에멀젼 및 그의제조 방법 | |
| WO2002034250A1 (fr) | Emulsions de matieres grasses | |
| HK1028877B (en) | Self-emulsifying formulation for lipophilic compounds | |
| MXPA00000996A (en) | Self-emulsifying formulation for lipophilic compounds | |
| JP2013203680A (ja) | ビタミンｅ誘導体を含有する血中滞留性薬物キャリアー粒子 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20201228 |